November 30, 2016 News

Cancer Therapy Advisor: “Is Drugmaker Funding for Patient Groups a Hidden Culprit in Rising Drug Prices?”

November 30, 2016

Bryant Furlow

Drugmakers contribute $50 million each year to the Leukemia and Lymphoma Society, more than a sixth of the group’s overall funding. Colon Cancer Alliance receives more than half of its funding—more than $1 million a year—from industry.1

PhRMA, the pharmaceutical industry’s lobby, asserts that drugmakers have a “natural alliance” with patient advocacy groups. But several experts who spoke with Cancer Therapy Advisor were blunt in their assessments of potential problems inherent to industry funding for patient groups.


Patients For Affordable Drugs is the only independent national patient organization focused exclusively on achieving policy changes to lower the price of prescription drugs.